Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...
Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...
Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 ...
Novavax Inc. closed 70.41% below its 52-week high of $23.86, which the company reached on June 6th.
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...
17h
Hosted on MSNNovavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi PartnershipNovavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...
GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results